 = Discovery stage. (16.60%, 2024)
|
 = Translation stage. (37.02%, 2024)
|
 = Clinically available. (46.38%, 2024)
|
|
|
| Description | Y/N | Source |
| Grants | yes | |
| Salary | yes | |
| Board Member | yes | GlycoPath, N-zyme Scientifics Board Member |
| Stock | yes | GlycoPath |
| Expenses | yes | |
| IP Royalty | yes |
| Planning to mention or discuss specific products or technology of the company(ies) listed above: | no |